Piramal Pharma releases Sustainability Report FY 2023-24

The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23

Piramal Pharma Solutions commissions ADC manufacturing expansion in Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.

Piramal Pharma takes a minority stake in Yapan Bio

The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space

Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr

This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs